Pure cerebellar ataxia due to bi‐allelic PRDX3 variants including recurring p.Asp202Asn
Annals of Clinical and Translational Neurology · 2023
DOI: 10.1002/acn3.51874 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2023. Verfasst von Stephanie Efthymiou und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK. Hauptthemen laut MEDLINE: Cerebellar Ataxia, Spinocerebellar Degenerations, Spinocerebellar Ataxias. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Biotechnology and Biological Sciences Research Council, Wellcome Trust.
Abstract (Originalsprache)
Bi‐allelic variants in peroxiredoxin 3 ( PRDX3 ) have only recently been associated with autosomal recessive spinocerebellar ataxia characterized by early onset slowly progressive cerebellar ataxia, variably associated with hyperkinetic and hypokinetic features, accompanied by cerebellar atrophy and occasional olivary and brainstem involvement. Herein, we describe a further simplex case carrying a reported PRDX3 variant as well as two additional cases with novel variants. We report the first Brazilian patient with SCAR32, replicating the pathogenic status of a known variant. All presented cases from the Brazilian and Indian populations expand the phenotypic spectrum of the disease by displaying prominent neuroradiological findings. SCAR32, although rare, should be included in the differential diagnosis of sporadic or recessive childhood and adolescent‐onset pure and complex cerebellar ataxia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
- Neurological Diseases Group, Postgraduate Program of Internal Medicine, Hospital de Clínicas, Federal University of Paraná, Curitiba, Paraná, Brazil.
- Neurogenetics Unit, 1st Department of Neurology, Eginition Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- 2nd Department of Radiology, Medical School, Attikon Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- Institute of Neurology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
- Genetika Laboratoty, Curitiba, Paraná, Brazil.
ORCID-Profile: Stephanie Efthymiou, Luiz E Novis, Luiz F Vasconcellos, Salmo Raskin, Helio A G Teive
Förderung
- Medical Research Council
- Biotechnology and Biological Sciences Research Council
- Wellcome Trust
- Multiple System Atrophy Trust
- Michael J. Fox Foundation for Parkinson's Research
- Rosetrees Trust
- Ataxia UK
- Brain Research UK
Zitieren
APA
Efthymiou, S., Novis, L. E., Koutsis, G., Koniari, C., Maroofian, R., Turchetti, V., Velonakis, G., Vasconcellos, L. F., Raskin, S., Srinivasan, V. M., Pagnamenta, A. T., Arun, Y. B., Kinhal, U. V., Gowda, V. K., Teive, H. A. G., & Houlden, H. (2023). Pure cerebellar ataxia due to bi‐allelic PRDX3 variants including recurring p.Asp202Asn. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.51874
Vancouver
Efthymiou S, Novis LE, Koutsis G, Koniari C, Maroofian R, Turchetti V, et al. Pure cerebellar ataxia due to bi‐allelic PRDX3 variants including recurring p.Asp202Asn. Annals of Clinical and Translational Neurology. 2023. doi:10.1002/acn3.51874
BibTeX
@article{Efthymiou2023,
author = {Efthymiou, Stephanie and Novis, Luiz E and Koutsis, Georgios and Koniari, Chrysoula and Maroofian, Reza and Turchetti, Valentina and Velonakis, Georgios and Vasconcellos, Luiz F and Raskin, Salmo and Srinivasan, Varunvenkat M and Pagnamenta, Alistair T and Arun, Yaramanchanahalli B and Kinhal, Uddhava V and Gowda, Vykuntaraju K and Teive, Helio A G and Houlden, Henry},
title = {Pure cerebellar ataxia due to bi‐allelic PRDX3 variants including recurring p.Asp202Asn},
journal = {Annals of Clinical and Translational Neurology},
year = {2023},
doi = {10.1002/acn3.51874}
}
EUVIMED